EUCTR2004-004275-11-DE进行中（未招募）不适用
An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks. - M2308
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male and/or female subjects from 12 to 18 years of age inclusive (Cohort A), above 18 to 50 years of age inclusive (Cohort B) and above 50 years of age (Cohort C).
- •2.Male and female patients with a diagnosis of seborrheic dermatitis. At screening and baseline, patients must have a moderate or severe SD assessed by a score of = 3 to the facial Investigator’s Global Assessment (IGA, Table 3-1). The SD will have to involve at least 5% of the Body Surface Area as determined by the Rule of Nine (Appendix 2). SD will be present in 3 areas of predilection (scalp, face, chest, intertriginous areas)
- •3.Except for SD, patients must be in good health as determined by past medical history, physical examination, vital signs and laboratory tests at screening.
- •4.Female subjects of child bearing potential must be using a double-barrier local contraception (i.e. intra-uterine device plus condom, or spermicidal gel plus condom, diaphragm plus spermicidal gel) or must have been surgically sterilized at least 6 months prior to screening. Surgical sterilization procedures must be supported with clinical documentation made available to sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. Postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion. Menopause will be confirmed by a plasma 17ß-estradiol concentration of <20 pg/mL and a plasma FSH level of >40 IU/L.
- •5.Adult patients must weigh at least 50 kg to participate in this study. Adolescent under 18 should have a body weight =10th percentile for age.
- •6.Vital signs (after 3 minutes resting measured in the supine position) which are within the following ranges:
- •oral body temperature between 35.0-37.5 °C
- •systolic blood pressure, 90-140 mm Hg
- •diastolic blood pressure, 50-90 mm Hg
- •pulse rate, 40 - 90 bpm
- •7.Subjects able to provide written informed consent prior to study participation. For patients below 18 years old, parents should be informed on the study procedures and provide their written informed consent too. Subject information and consent forms generated by the investigator must be approved by the sponsor prior to submission to the Ethics Committee (EC)/Institutional Review Board (IRB). A copy of the subject information and consent forms approved by the EC/IRB must be forwarded to the sponsor prior to study initiation.
- •8.Subjects able to communicate well with the investigator and comply with the requirements of the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients with atopic dermatitis, Netherton’s syndrome or psoriasis.
- •2.Clinically significant findings during the physical examination (except seborrheic dermatitis), or laboratory abnormalities.
- •3.Symptoms of a significant clinical illness other than SD in the three-week period preceding the entry in the study.
- •4.Presence of any viral or fungal or bacterial skin infection.
- •5.Patients with known serious adverse reactions or hypersensitivity to pimecrolimus, tacrolimus, macrolactam or to any of the excipients (see section 3.3.1) of the study medication.
- •6.Women who are pregnant or breastfeeding. Female adolescents who have reached menarche and do not use double barrier contraception during and at least until 4 weeks after the end of treatment.
- •7.Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
- •8.Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
- •9.History of cancer, skin malignancy or lymphoproliferative disorders.
- •10.History of immunocompromise, including a positive HIV (ELISA and Western blot) test result.
- •11.A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- •12.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study. The investigator should be guided by evidence of any of the following:
- •clinical evidence of liver disease or liver injury as indicated by abnormal liver function tests such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin. SGPT will have to be strictly within the normal range before inclusion, GGT and alkaline phosphatase must not exceed twice the upper limit of the normal range, and serum bilirubin should not exceed the value of 27 µmol/L (1.6 mg/dL).
- •history or presence of impaired renal function as indicated by abnormal creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria);
- •polymorphonuclears <1500/µL or platelets <100’000/µL at inclusion.
- •13.Use of any prescription drug or over-the-counter (OTC) medication within 2 weeks prior to dosing. Paracetamol is acceptable, but must be documented in the Concomitant medications / Significant non-drug therapies page of the CRF.
- •14.Use of systemic corticosteroids (i.e. oral, intravenous, intra-articular, rectal) within four (4) weeks prior to baseline.
- •15.Phototherapy within four (4) weeks prior to baseline.
- •16.Topical therapy (e.g. tar, topical corticosteroids, topical anti-fungals,) within 3 days prior to baseline, with the exception of emollients. Topical tacrolimus within 2 weeks prior to baseline.
- •17.Treatment with nephrotoxic drugs within two (2) weeks prior to baseline (aminoglycosides, amphotericin B, colchicine).
- •18.Treatment with any CYP3A4 inhibitors or inducers within two (2) weeks prior to baseline and during the study course.
研究者
相似试验
进行中（未招募）
不适用
Open label clinical trial to determine the blood ethanol concentration following repeated administration of Bronchicum Elixir to children (1 to 12 years) with acute bronchitis.acute bronchitisEUCTR2009-014904-73-DECassella-med GmbH & Co. KG24
已完成
4 期
A clinical study to vaccinate healthy adults with a single human dose of a licensed Typhoid Conjugate Vaccine and collection of immune sera for development of testing standards for anti- typhoid antibody estimation.CTRI/2018/01/011500Biological ELimited
已完成
1 期
A study in healthy male volunteers to investigate how the test medicine is taken up, processed, and removed from the bodyPharmacokinetics, mass balance and metabolite profiles of NRD135S.E1 in healthy adult male volunteersISRCTN51059297ovaremed AG (Switzerland)8
已完成
1 期
Oral Bioavailability of Solid Formulation of GLPG1205 With and Without FoodHealthyNCT02143856Galapagos NV12
进行中（未招募）
不适用
An open – label clinical trial to study pharmacokinetics (PK) of different levels (0.125 mg, 0,25 mg, 0.5 mg) of pramipexole taken once a day by month in children who can accepte stable pramipesole doses for the treatment of Restless Leg Syndrome (RLS) – A disorder which feel the urge to move the legs to reduce the unpleasant sensatioRestless Legs SyndromeMedDRA version: 14.0Level: PTClassification code 10058920Term: Restless legs syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002774-23-Outside-EU/EEABoehringer Ingelheim Pharmaceuticals, Inc.36